

**Morning Sessions - Hall A**

**Italian Sessions**

---

**09:00 - 10:30 New Concepts Ocular Inflammation and Infection Treatment. The Italian Point of View** Hall A

Chairperson: **P. Aragona**, Italy

---

09:00 **The Treatment of Inflammation in Course of Dry Eye. Il Trattamento Dell'inflammation in Corso Di Occhio Secco**  
*P. Aragona (Italy)*

09:22 **The Management of Inflammation in Allergic Eye Diseases. La Gestione Dell'inflammation Nelle Malattie Allergiche Oculari.**  
*A. Lambiase (Italy)*

09:44 **The Treatment of Post-Operative Ocular infections. Il Trattamento Delle Infezioni Oculari Nel Post-Operatorio**  
*L. Spadea (Italy)*

10:06 **Treatment of Post-Cataract Inflammation. Il Trattamento Dell'inflammation Dopo Intervento di Cataratta**  
*R. Mencucci (Italy)*

10:30 - 11:00 **Coffee Break**

---

**11:00 - 12:30 Updates in the Treatments of Retinal Diseases** Hall A

Chairpersons: **F. Bandello**, Italy

**R. Brancato**, Italy

---

11:00 **AntiVEGF for Diabetic Macular Edema**  
*P. Iacono (Italy)*

11:15 **AntiVEGF for Choroidal Neovascularization Secondary to AMD**  
*U. Introvini (Italy)*

11:30 **AntiVEGF for Choroidal Neovascularization Secondary to Pathologic Myopia**  
*S. Saviano (Italy)*

11:45 **Steroids for Diabetic Macula Edema**  
*C. Parravano (Italy)*

12:00 **Steroids and AntiVEGF for Macular Edema Secondary to Retinal Vein Occlusions**  
*R. Lattanzio (Italy)*

12:15 **Antivasculogenesis**  
*G. Tremolada (Italy)*

**Afternoon Sessions - Hall A**

---

**14:00 - 14:45 DME Session** Hall A  
Chairpersons: **P. Lanzetta**, Italy  
**J. Sahel**, France

---

14:00 **Triamcinolone Acetonide and Diabetic Macular Edema**

*P. Lanzetta, D. Veritti (Italy)*

14:09 **Laser Plus Steroids for DME**

*F. Bandello (Italy)*

14:18 **Laser Plus Anti-VEGF for Diabetic Macular Edema**

*A.J. Augustin, J. Kirchhof (Germany)*

14:27 **Role of The Lallikrein-Kinin System in Diabetic Retinopathy**

*J. Sahel<sup>1</sup>, R. Couture<sup>3</sup>, M. Pouliot<sup>3</sup>, S. Talbot<sup>3</sup>, E. Vaucher<sup>3</sup>, M. Paques<sup>1</sup>,  
B. El-Mathari<sup>1</sup>, A. Bemelmans<sup>1</sup>, C. Belichard<sup>1</sup>, D. Pruneau<sup>1</sup>  
<sup>1</sup> France, <sup>2</sup> UK, <sup>3</sup> Canada*

Interactive Discussion with the Audience

14:36 **Sirolimus and mTOR Inhibition for the Treatment of Diabetic Macular Edema**

*P. Dugel (USA)*

---

**14:45 - 15:45 Pharmacologic Inhibition of Diabetic Retinopathy** Hall A  
Chairperson: **A. Das**, USA

---

14:45 **Inhibition of p38 MAPK Inhibits Early Stages of Diabetic Retinopathy**

*T. Kern, Y. Du, G. Li, G. Alton, M. Niesman, J. Monahan (USA)*

15:00 **Metabolic Memory and Potential Therapeutics**

*R. Kowluru (USA)*

15:15 **Cellular Therapy of Vasodegenerative Diseases in Diabetic Retinopathy**

*A. Bhatwadekar<sup>1</sup>, E. Guerin<sup>1,2</sup>, J. Yagna<sup>1</sup>, C. Sergio<sup>1</sup>, C. Sheridan<sup>3</sup>, D. Kent<sup>2</sup>,  
L. Kennedy<sup>1</sup>, M. Lansang<sup>1</sup>, F. Ruscetti<sup>1</sup>, S. Bartelmez<sup>1</sup>, M. Grant<sup>1</sup>  
<sup>1</sup> USA, <sup>2</sup> Ireland, <sup>3</sup> United Kingdom*

15:30 **Inhibitors of Advanced Glycation Endproducts (AGEs) in the Treatment of Diabetic Retinopathy**

*A. Stitt (UK)*

15:45 - 16:15 **Coffee Break**

**Afternoon Sessions - Hall A**

---

**16:15 - 17:45 Advances in the Management of Glaucoma Progression & Devices for Glaucoma** Hall A  
Chairpersons: **H. Levkovitch-Verbin**, Israel  
**J. Brandt**, USA

---

**Advances in the Management of Glaucoma Progression**

- 16:15 **Surgical Treatment as Initial Therapy for Glaucoma**  
*S. Gandolfi (Italy)*
- 16:27 **Advances in Fixed-Combination Therapy of Glaucoma**  
*G. Hollo (Hungary)*
- 16:39 **Intravitreal Cell-Encoated Drug Therapy**  
*J. Jonas (Germany)*
- 16:51 **Risk Models and Glaucoma Progression**  
*J. Brandt (USA)*
- 17:03 **The Importance of Preservative Free Drops in the Treatment of Glaucoma**  
*C. Baudoin (France)*

**Devices for Glaucoma**

- 17:15 **CO2 Laser Assisted Deep Sclerectomy ("CO2 LADS") - a Novel Technology for Treatment of Glaucoma**  
*N. Geffen<sup>1</sup>, Y. Ton<sup>1</sup>, R. Thomas<sup>2</sup>, S. Anisimova<sup>3</sup>, F. Gil<sup>4</sup>, E.I. Assia<sup>1</sup>*  
*<sup>1</sup> Israel, <sup>2</sup> India, <sup>3</sup> Russia, <sup>4</sup> Mexico*
- 17:27 **Servo-Controlled Tonography with a Nanofabricated Pressure Sensor**  
*J. Brandt (USA)*
- 18:00 **Get Together Reception (Exhibition)**

**Afternoon Sessions - Hall B**

---

**14:00 - 14:45 Vascular Targets** Hall B  
Chairperson: **L. Schmetterer**, Austria

---

14:00 **The Endothelium**

*L. Schmetterer (Austria)*

14:15 **Inflammation and Blood Flow**

*T. Nagaoka (Japan)*

14:30 **Ischemia and the Ganglion Cell**

*N. Osborne (UK)*

---

**14:45 - 15:45 Anterior Segment Imaging** Hall B  
Chairperson: **P. Asbell**, USA

---

14:45 **The Clinical Use of Anterior Segment Optical Coherence Tomography**

*J. Mehta (Singapore)*

14:55 **In Vivo Confocal Microscopy Evaluation of Inflammatory Changes in the Ocular Surface**

*C. Baudouin, A. Labbe, B. Dupas, E. Brasnu (France)*

15:05 **Clinical Applications of Pentacam Scheimpflug System**

*O. Ucakhan-Gunduz (Turkey)*

15:15 **Advancements in Confocal Microscopy**

*R. Beuerman, H. Zhu (Singapore)*

15:25 **Study on the Tear Dynamics and its Related Clinical Queries by Developing the Anterior Segment OCT and the Tearscope Technology**

*L. Fan, C. Qi, S. Meixiao (China)*

15:35 **Question & Answers**

Panel: J. Mehta, C. Baudouin, O. Ucakhan-Gunduz, R. Beuerman, L. Fan

15:45 - 16:15 **Coffee Break**

---

**Afternoon Sessions - Hall B**

---

**16:15 - 17:45 Neuroprotection**

Hall B

Chairperson: **W. Lagreze**, Germany

---

- 16:15 **Neuroprotection - Bridging the Gap Between the Lab and the Clinic**  
*W. Lagreze (Germany)*
- 16:33 **Stem Cell Neuroprotection**  
*K. Martin (UK)*
- 16:51 **The Role of Histone-Deacetylase-Inhibitors in Neuroprotection**  
*J. Biermann (Germany)*
- 17:09 **Mitochondria in Cell Death and Use of Alpha-Lipoic Acid for Neuroprotection**  
*N. Osborne (UK)*
- 17:27 **Utilizing Acute Optic Neuritis to Investigate Neuroprotection Therapy in Human Trial**  
*M. Kupersmith (USA)*
- 18:00 **Get Together Reception (Exhibition)**

**Morning Sessions - Hall A**

---

**08:00 - 09:00 Anterior Segment Diseases: Management of Special Cases - Discussion** Hall A  
Chairpersons: **P. Asbell, USA**  
**H. Kaufman, USA**

---

Special Cases will be presented by:

P. Asbell (USA)

R. Beuerman (Singapore)

I. Barequet (Israel)

**Interactive Discussion with the Audience**

---

**09:00 - 09:45 Anti-angiogenic Agents for Atypical Conditions** Hall A  
Chairpersons: **K. Drenser, USA**  
**F. Bandello, Italy**

---

09:00 **Anti- VEGF Therapy for Atypical Indications**  
*J. Mones, L.L. Arias (Spain)*

09:11 **Ranibizumab for the Treatment of Choroidal Neovascularization Not Due to Age-Related Macular Degeneration: 12-Month Data**  
*J.S. Heier, D.M. Brown, I.K. Kim, T.A. Ciulla, P. Abraham, J.M. Bankert, S.G. Chong, P.E. Daniel*  
USA

09:22 **Anti VEGF Therapy for Myopic CNV**  
*J. Mones, L. Arias, L. Amselem (Spain)*

09:33 **Anti-VEGF for ROP**  
*K. Drenser (USA)*

---

**09:45 - 10:30 A New Option in Topical Glaucoma Therapy, Sponsored by Santen**

---

Main Presentations: Hall B

Overflow Screen: Hall C

10:30 - 11:00 **Coffee Break**

---

**11:00 - 11:45 Inflammation Control for Getting the Best From Ocular Surgery, Sponsored by Bausch & Lomb**

---

Main Presentations: Hall B

Overflow Screen: Hall C

---

**11:45 - 12:30 Retinal Degenerations**

Hall A

Chairpersons: **A. Reibaldi**, Italy  
**D. Saperstein**, USA

---

11:45 **Neuroprotection in Retinal Degenerations, An Overview**

*J. Sahel, S. Picaud (France)*

11:56 **Overview of Retinal Degenerations**

*J. Sahel, I. Audo, S. Mohand-Said, M. Paques (France)*

12:07 **Cone Viability Factors: Molecular and Functional Studies**

*J. Sahel<sup>1</sup>, Y. Yang<sup>1</sup>, T. Cronin<sup>1</sup>, C. Jaillard<sup>1</sup>, I. Lee-Rivera<sup>1</sup>, I. Audo<sup>1</sup>, R. Fridlich<sup>1</sup>,  
S. Reichman<sup>1</sup>, E. Clerin<sup>1</sup>, D. Zack<sup>3</sup>, S. Picaud<sup>1</sup>, J. Bennet<sup>1</sup>, O. Poch<sup>1</sup>,  
S. Mohand-Said<sup>1</sup>, T. Leveillard<sup>1</sup>*  
*<sup>1</sup> France, <sup>2</sup> UK, <sup>3</sup> USA*

12:18 **Cis Beta Carotene for Congenital Stationary Night Blindness**

*Y. Rotenstreich, D. Harats, A. Shaish, E. Pras, M. Belkin (Israel)*

---

**12:30 - 13:45 Retina Lunch Session, Sponsored by Allergan**

---

Main Presentations: Hall B

Overflow Screen: Hall C

**Morning Sessions - Hall B**

---

**09:00 - 09:45 Novel Therapies of Retinal Neovascularization - Preclinical Studies** Hall B  
Chairperson: **A. Das**, USA

---

09:00 **PPAR-beta in Retinal Angiogenesis**

*J. Penn, G. McCollum, S. Yanni, R. Yang (USA)*

09:11 **Cell Based Delivery of Neurotrophics and Anti-Angiogenesis for Retinal Neovascularization - Preclinical Studies**

*M. Friedlander (CA, USA)*

09:22 **CD9 as a Therapeutic Target in Ocular Diseases**

*T. Sakamoto, T. Kamisasanuki, K. Kosai (Japan)*

09:33 **AlphaB-Crystallin as a Therapeutic Target for Ocular Angiogenesis**

*D. Hinton, R. Kannan (USA)*

---

**09:45 - 10:30 S13 - A New Option in Topical Glaucoma Therapy, Sponsored by Santen** Hall B  
Chairperson: **S. Miglior**, Italy

---

09:45 **Ocular Surface and Glaucoma Medications – New Insights**

*C. Baudouin (France)*

09:57 **Preservative Free Prostaglandin – Experiences in Clinical Use**

*A. Hommer (Austria)*

10:09 **Review of the Pharmacologic Profile of Tafluprost - Comparison with Other Prostaglandins**

*J. Stjernschantz (Sweden)*

10:21 **Discussion**

10:30 - 11:00 **Coffee Break**

---

**11:00 - 11:45 Inflammation Control for Getting the Best From Ocular Surgery, Sponsored by Bausch & Lomb** Hall B  
Chairpersons: **S. Bonini**, Italy  
**M. Rolando**, Italy

---

11:00 **Introduction: Inflammation as a Risk Factor for Anterior Segment Surgery**  
*S. Bonini (Italy)*

11:05 **The Selection and Preparation of Patient and Pre-Surgical Approach**  
*M. Rolando (Italy)*

11:25 **Cataract Surgery: The Peri-/Post-Operative Approach**  
*R. Mencucci (Italy)*

---

---

**11:45 - 12:30 Advances in Retinal Imaging, Sponsored by Heidelberg** Hall B  
Chairperson: **J. Heier, USA**

---

11:45 **The Importance of Registration and Multi-Modality Imaging in the Diagnosis and Management of Retinal Diseases**

*J.S. Heier (USA)*

12:00 **Failure of Anti-VEGF Therapy – Recognition and Management with ICGA**

*G. Shah (USA)*

12:15 **Fundus Autofluorescence and OCT Imaging in Dry AMD**

*J. Mones, L.L. Arias, M. Biarnes (Spain)*

---

**12:30 - 13:45 Retina Lunch Session, Sponsored by Allergan** Hall B  
Chairpersons: **F. Bandello, Italy**  
**J. Sahel, France**

---

12:45 **Introduction and Welcome**

12:50 **In Vivo Imaging (AO) in Clinical Practice**

*J. Sahel (France)*

13:00 **Role of Inflammation in ME**

*J.A. Haller (USA)*

13:10 **Use of Steroids to Reduce Macular Edema and the Emerging Concepts of Steroid Structure and Activity in Ocular Cells and Tissues**

*B. Kuppermann (USA)*

13:20 **POSURDEX® - Phase 3 RVO Results; A New Option for Macula Edema**

*F. Bandello (Italy)*

13:35 **Macula Edema – With All This New Data Where To From Here?**

*M. De Smet (Netherlands)*

**Morning Sessions - Hall C**

---

**08:00 - 09:00 My Dilemma in Glaucoma - Case Presentation and Discussion** Hall C  
Chairperson: **H. Verbin-Levkovitch, Israel**

---

**Panel of Speakers:**

**What Kind of Glaucoma this Patient Suffers From?**

G. Hollo (Hungary)

**Glaucoma and Uveitis in Coats' Disease**

J. Brandt (USA)

**Glaucoma Surprises**

B. Katz (USA)

**Persistent Ocular Hypertension Resistant to Topical Treatment- What is Next?**

J. Jonas (Germany)

**Double Ahmed Valve**

N. Geffen (Israel)

---

**09:00 - 09:45 Toxicology** Hall C  
Chairperson: **R. Fraunfelder, USA**

---

09:00 **Retinal Toxicity of Drugs**

K. Chalam (USA)

09:11 **Ocular Safety in the Treatment of Retinal Diseases: The Overlooked Corneal and Retinal Neural Cells**

E. Midena (Italy)

09:22 **Active Sureveillance of Adverse Drug Reactions**

K. Winthrop (USA)

09:33 **Preclinical Safety Assessment of Ocular Findings**

C. Safholm (Sweden)

---

**09:45 - 10:30 A New Option in Topical Glaucoma Therapy, Sponsored by Santen** Hall C

---

Main Presentations: Hall B

Overflow Screen: Hall C

10:30 - 11:00 **Coffee Break**

**11:00 - 11:45 Inflammation Control for Getting the Best From Ocular Surgery,  
Sponsored by Bausch & Lomb** Hall C

---

Main Presentations: Hall B

Overflow Screen: Hall C

---

**11:45 - 12:30 Cationic Emulsion for Improved Ocular Safety and Efficacy in the  
Perspective of Glaucoma and Dry Eye Management- Sponsored by  
Novalgali** Hall C  
Chairperson: **C. Baudouin**, France

---

11:45 **Introduction**

11:50 **Biopharmaceutical Aspects of Cationic Emulsions**

*J. Garrigue (France)*

11:58 **Dry Eye Clinical Outcomes with Cationic Emulsions**

*M. Amrane (France)*

12:06 **Ocular Safety of Cationic Emulsions**

*H. Liang (France)*

12:14 **Safety Improvement for the Ocular Surface with an Antiglaucomatous Prostaglandin  
in Cationic Emulsion Formulation**

*F. Baudouin (France)*

12:22 **Q&A**

---

**12:30 - 13:45 Retina Lunch Session, Sponsored by Allergan**

---

Main Presentations: Hall B

Overflow Screen: Hall C

---

**Afternoon Sessions - Hall A**

---

**14:00 - 17:00 Wet AMD**

Hall A

Chairpersons: **A.J. Augustin**, Germany  
**P. Kaiser**, USA

---

14:00 **Role of Inflammation in AMD and DR**

*A.J. Augustin (Germany)*

14:12 **Comparison of AMD Treatment Trials**

*J.A. Haller, M. Maguire, S.L. Fine, D.F. Martin, CATT Study Group (USA)*

Overflow Screen: Hall C

14:24 **Integrin Inhibition for Exudative AMD**

*J.S. Heier<sup>1</sup>, A.J. Berman<sup>1,1</sup>, G. Zanh<sup>2</sup>, D.T. Shima<sup>1,3</sup>, A.P. Adamis<sup>1,1</sup>*  
*<sup>1</sup>USA, <sup>2</sup>Germany, <sup>3</sup>UK*

14:36 **Targeting Platelet Derived (PDGF) and Vascular Endothelial (VEGF) Growth Factors for Neovascular AMD – Phase 1 Study**

*P. Kaiser (USA)*

14:48 **Efficacy of a Topical Tubulin Inhibitor, OC-10X, in a Non-Human Primate Model of Exudative AMD**

*C. Greven, P. Williams, F. Lattanzio, S. English (USA)*

15:00 **Topical Ophthalmic Pazopanib Therapy for Exudative Age-Related Macular Degeneration**

*M. Johnson<sup>1</sup>, R.P. Danis<sup>1</sup>, M. Tolentino<sup>1</sup>, G. Staurenghi<sup>2</sup>, P. Kaiser<sup>1</sup>, J. Slakter<sup>1</sup>, L. Ye<sup>1</sup>, C. Xu<sup>1</sup>, J. Wurzelmann<sup>1</sup>, P. Lebowitz<sup>1</sup>, M. McClaughlin<sup>1</sup>*  
*<sup>1</sup>USA, <sup>2</sup>Italy*

15:12 **Sirolimus and mTOR Inhibition for the Treatment of Wet AMD**

*P. Dugel (USA)*

15:24 **18-Month Follow-up Results for Patients with Exudative AMD Treated with VEGF Trap-Eye who Entered an Extension Study from a Randomized, Dose- and Interval-Ranging Phase 2 Study**

*J.S. Heier (USA)*

15:36 **Lucentis (Ranibizumab) versus Avastin (Bevacizumab) for CNV/AMD**

*N. Fischer, R. Jung, G. Heilweil, D. Varssano, M. Goldstein, A. Barak, A. Loewenstein*  
*Israel*

**15:45-16:15 Coffee Break**

**14:00 - 17:00 Wet AMD (Cont.)**

Hall A

16:15 **Macular EpiRetinal Brachytherapy in Treated Age Related Macular Degeneration Patients (MERITAGE)**

*P. Dugel<sup>1</sup>, T. Jackson<sup>2</sup>, J.S. Heier<sup>1</sup>*

<sup>1</sup> USA, <sup>2</sup> England

16:27 **Externally-Applied Stereotactic Orthovoltage Irradiation for Age-Related Macular Degeneration: Results of a Phase I Clinical Trial**

*P. Kaiser (USA)*

16:39 **Complement Allele Association with Baseline Lesion Characteristics and Visual Acuity Outcomes following Ranibizumab Treatment**

*M. Cooney (USA)*

16:51 **Q&A**

---

**17:00 - 17:45 WET AMD Combination Therapy**

Hall A

Chairpersons: **A. Pollack**, Israel

**P. Lanzetta**, Italy

---

17:00 **Triple Therapy for Wet AMD**

*A.J. Augustin, J. Kirchhof (Germany)*

17:09 **Verteporfin, Triamcinolone Acetonide and Lucentis in CNV Secondary to AMD The VITAL Study**

*P. Lanzetta, D. Veritti (Italy)*

R. Beuerman, USA

17:18 **Combination Therapy in CNV and the MONT BLANC Study**

*P. Lanzetta, D. Veritti (Italy)*

17:27 **Updates on the Studies of Fluocinolone Acetonide Intravitreal Insert (Iluvien™) for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration**

*Q.D. Nguyen, The Iluvien Investigators (USA)*

17:36 **A Comparison of Combination Therapy Trials for Wet AMD**

*P. Kaiser (USA)*

**Afternoon Sessions - Hall B**

---

**14:00 - 14:45 Gene Therapy** Hall B  
Chairperson: **C. Paterson, USA**

---

11:45 **All Eyes on RNAi: Recent Promise and Progress in Ocular Gene Therapy**  
*D. Grimm (Germany)*

12:00 **New Approaches to Genetic Screening for Inherited Eye Diseases**  
*D. Simpson (UK)*

12:15 **The Quest for Genetic Therapy for AMD**  
*A. Scaria (USA)*

---

**14:45 - 15:45 Reading Centers** Hall B  
Chairperson: **R.P. Danis, USA**

---

14:45 **The Clinical Site – Reading Center Partnership in Clinical Trials**  
*R.P. Danis (USA)*

14:57 **Reading Centers in Clinical Trials – The Industry Perspective**  
*M. Sheetz (USA)*

15:09 **Reading Centers in Clinical Trials: The CRO Perspective**  
*A. Lindblad (USA)*

15:21 **Concordance and Training for Fundus Fluorescein and Indocyanine Green  
Angiographic Interpretation within Ophthalmic Reading Centres**  
*U. Chakravarthy, L. Patton, A. Muldrew (Northern Ireland, UK)*

15:33 **The Role of Reading Center Eligibility Determination in Clinical Trials**  
*M. Ip (USA)*

15:45 - 16:15 **Coffee Break**

**16:15 - 17:45 Clinical Trials Endpoints: The Common and Unique Characteristics of  
Clinical Endpoints Across the Globe**

Chairperson: **P. Kaufman**, USA

---

Devices:

**US Perspective**

*M. Eydelman (USA)*

**Japan Perspective**

*M. Sawa (Japan)*

Therapeutic:

**FDA Point of View**

*W. Chambers (USA)*

**EU Point of View**

*K. Wickstrom (Sweden)*

Panel Discussion:

P. Kaufman, USA, R. Danis, USA, M. Eydelman, USA, M. Sawa, Japan, K. Wickstrom, Sweden

**Afternoon Sessions - Hall C**

---

**14:00 - 14:45 Antioxidants** Hall C  
Chairperson: **P. Bernstein, USA**

---

14:00 **Nature and Nurture-Genes, Lifestyles, and Nutrition-Predict Macular Degeneration**  
*J. Seddon (USA)*

14:15 **Anti-Oxidant and Anti-Inflammatory Compounds in Retinal Degeneration Studies-  
from Molecular Mechanisms to Therapeutic Strategies**  
*R. Anderson, N. Mandal (USA)*

14:30 **Development of Improved Animal Models for the Study of Nutritional Interventions  
Against Retinal Disease**  
*P. Bernstein, B. Li, L. Aihua, P. Vachalli (USA)*

---

**14:45 - 15:45 The Diagnostoc Challenge in Uveitis** Hall C  
Chairpersons: **P. Pivetti-Pezzi, Italy**  
**M. Accorinti, Italy**

---

14:45 **An update on PCR-guided Therapy for Anterior Uveitis**  
*G. Cheung, S. Chee (Singapore)*

15:05 **The Challenge of Tuberculosis in Inflammatory Ocular Diseases**  
*T. Albin (USA)*

15:25 **When Inflammation Stops and Atrophy Starts**  
*M. Accorinti (Italy)*

15:45 - 16:15 **Coffee Break**

**16:15 - 17:27 New Treatment for Dry Eyes**

Hall C

Chairperson: **P.A Asbell, USA**

---

- 16:15 **Inflammation in Meibomian Gland Dysfunction and Dry Eye Interaction and Therapeutic Implications**  
*H. Kaufman (USA)*
- 16:27 **Current State of Understanding Regarding the Immunopathogenesis of Dry Eyes and Implications for Therapy**  
*R. Dana (USA)*
- 16:39 **Treatment of Dysfunctional Tear Syndrome by Means of Lipid-based Tear Substitutes**  
*M. Rolando<sup>1</sup>, F. Grus<sup>1</sup>*  
*<sup>1</sup> Italy, <sup>2</sup> Germany*
- 16:51 **MIM-D3, A Small Molecule NGF Mimetic for Dry Eye Treatment**  
*G. Cumberlidge, T. Lama, K. Meerovitch (Canada)*
- 17:03 **New Formulation for Dry Eye Treatment based on Liposomes and Bioadhesive Polymers**  
*R. Herrero-Vanrell, M. Vicario, E. Vico, B. de las Heras, J.M. Benitez del Castillo, I.T. Molina-Martinez*  
*Spain*
- 17:15 **Topical Amnion Membrane Extract Promotes Corneal Epithelial Wound Healing**  
*K. Kenyon<sup>1,2</sup>, L. Vedovelli<sup>1</sup>, E. Ghinelli<sup>1,3</sup>*  
*<sup>1</sup> USA, <sup>2</sup> Germany, <sup>3</sup> Italy*
- 17:27 - 17:45 **Discussion and Q&A**

**Morning Sessions - Hall A**

---

**08:00 - 09:00 Wet AMD Panel**

Hall A

Chairperson: **G. Soubrane**, France

---

08:00 **HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-related Macular Degeneration (AMD): Two-year Safety and Efficacy Results**  
*M. Cooney (USA)*

08:15 **Discussion**

**Panel Members:**

F. Bandello, Italy, M. Johnson, USA, M. Cooney, USA, J. Cardillo, Brazil

**09:00 - 10:30 Dry AMD**

Hall A

Chairpersons: **J. Heier**, USA  
**J. Mones**, Spain

---

09:00 **Complement Inhibition for AMD - Overview**

*F. Behar (France)*

09:10 **Anti-C5 (Ophthotech)**

*J. Mones (Spain)*

09:20 **Complement C3 Inhibitor POT-4 in AMD**

*C. Francois<sup>1</sup>, G. Coscas<sup>1,2</sup>, P. Rosenfeld<sup>1,1</sup>, F. Grossi<sup>1</sup>, S. Bakri<sup>1</sup>, D. Boyer<sup>1</sup>, S. Kaushal<sup>1</sup>, P. Deschatelets<sup>1</sup>, J. Slakter<sup>1</sup>*  
*<sup>1</sup> USA, <sup>2</sup> France*

09:30 **Immune-Based Systemic Therapy with Copaxone for Dry Age-Related Macular Degeneration**

*A. Pollack, Y. Shoshani, G. Landa, H. Katz, O. Butovsky, M. Schwartz (Israel)*

09:40 **A Phase 2 Study of Encapsulated CNTF Secreting Cell Implant (NT-501) in Patients with Geographic Atrophy Associated with Dry AMD**

*J.S. Heier (USA)*

09:50 **11-cis-retinal Analogs for the Treatment of Age-Related Retinopathies**

*D. Saperstein (USA)*

10:00 **Macular Pigment Imaging in AREDS II Participants: An Ancillary Study of AREDS II Subjects Enrolled at the Moran Eye Center**

*P. Bernstein, F. Ahmed, W. Gellermann, M. Sharifzadeh, I. Ermakov (USA)*

10:10 **Alprostadiol for Dry Age Related Macular Degeneration (AMD)**

*A.J. Augustin, J. Kirchhof (Germany)*

10:20 **ACU4429 – Visual Cycle Modulator as Potential Therapy for Dry AMD**

*N. Boman, R. David, D. Birch, R. Kubota (USA)*

10:30 - 11:00 **Coffee Break**

**11:00 - 12:30 Treatments for Retinal Vein Occlusion**

Hall A

Chairpersons: **J. Haller**, USA

**A. Lowenstein**, Israel

---

- 11:00 **Ozurdex: Results of a Randomized Controlled Clinical Trial of an Intravitreal Dexamethasone Delivery System for the Treatment of Macular Edema Associated with Retina Vein Occlusion**  
*J.A. Haller*<sup>1</sup>, *DDS Study Group*<sup>2</sup>  
<sup>1</sup> USA, <sup>2</sup> CA
- 11:12 **SCORE Study Report #5**  
*M. Ip* (USA)
- 11:24 **SCORE Study Report #6**  
*M. Ip* (USA)
- 11:36 **Lucentis/ Ranibizumab for Branch Retinal Vein Occlusion: BRAVO**  
*N. Fischer*, *M. Goldstein*, *A. Loewenstein* (Israel)
- 11:48 **Lucentis/ Ranibizumab for Central Retinal Vein Occlusion: CRUISE**  
*N. Fischer*, *M. Goldstein*, *A. Loewenstein* (Israel)
- 12:00 **Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion**  
*V. Gonzalez* (USA)
- 12:12 **Subtenon's Triamcinolone for the Treatment of Macular Edema Associate with CRVO/BRVO**  
*T.J. Wolfensberger* (Switzerland)
- 

**12:30 - 13:30 Optimal Glaucoma Management Lunch Session, Sponsored by Allergan**

---

Main Presentations: Hall B

Overflow Screen: Hall C

**Morning Sessions - Hall B**

---

**09:00 - 09:45 Novel Therapeutic Approaches for Glaucoma** Hall B  
Chairpersons: **J. Jonas**, Germany  
**P. Kaufman**, USA

---

09:00 **The Role of the Cerebrospinal Fluid Pressure in the Pathogenesis of Glaucomatous Optic Neuropathy: Implications for Medical Therapy**  
*J. Jonas (Germany)*

09:09 **Stem Cells Treatment for Glaucoma**  
*H. Levkovitch-Verbin (Israel)*

09:18 **Axonal Regeneration The Key to Therapeutic Advancement?**  
*S. Thanos (Germany)*

09:27 **Preventing Axonal Degeneration in Glaucoma**  
*K. Martin (UK)*

09:36 **Aqueous Outflow Biology and Therapeutics: What's New?**  
*P. Kaufman (USA)*

---

**09:45 - 10:30 The Therapeutic Challenge of Biologic Therapy** Hall B  
Chairpersons: **K. Tabbara**, Saudi Arabia  
**A. Okada**, Japan

---

09:45 **Should We use These as First-line Therapy?**  
*M. deSmet (Netherlands)*

10:00 **How Big is the Risk of Infection, Malignancy and Other Complications?**  
*E. Suhler (USA)*

10:15 **Troubleshooting: What Should We Do When Infusion Reactions Occur or Patients Stop Responding to Therapy?**  
*R. Priori (Italy)*

10:30 - 11:00 **Coffee Break**

**11:00 - 11:45 Gaseous Neurotransmitters and the Eye**

Hall B

Chairperson: **F. Drago**, Italy

---

11:00 **Nitric Oxide/Carbon Monoxide in the Eye**

*C. Bucolo, F. Drago (Italy)*

11:11 **Role of Nitric Oxide in the Control of Ocular Blood Flow**

*L. Schmetterer (Austria)*

11:22 **Nitric Oxide in the Regulation of Intraocular Pressure**

*H. Vapaatalo, H. Kotikoski, O. Oksala, P. Alajuuja, E. Aine, J. Maenpaa (Finland)*

11:33 **Heme Oxygenase-1-Related Carbon Monoxide and Flavonoids in Ischemic/Reperfused Rat Retina**

*B. Juhasz, M. Szabo, R. Gesztelyi, B. Varga, A. Kemeny-Beke, I. Bak, D. Haines, A. Tosaki  
Hungary*

---

**11:45 - 12:30 S34 - Imaging**

Hall B

Chairperson: **S. Krupsky**, Israel

---

11:45 **Microperimetry of the Macula**

*E. Midena (Italy)*

12:00 **Metabolic Imaging of the Retina**

*E. Stefansson, S. Hardarson (Iceland)*

12:15 **Reproducibility of Measurement with the RTVue Fourier-Domain OCT in Glaucoma**

*G. Hollo, A. Garas (Hungary)*

---

**12:30 - 13:30 Optimal Glaucoma Management Lunch Session, Sponsored by Allergan Hall B**

Chairpersons: **G. Megavand**, Switzerland

**A. Bron**, France

---

12:30 **Introduction and Welcome**

12:32 **Optimal Glaucoma Management**

*G. Megavand (Switzerland)*

12:42 **Lumigan 0.01% a New Therapy for 1st line Glaucoma Management**

*P. Denis*<sup>1</sup>, *A. Batoosingh*<sup>1,2</sup>, *V. Shu*<sup>2</sup>, *R. Schiffman*<sup>2</sup>

<sup>1</sup> France, <sup>2</sup> USA

12:52 **Efficacy in Glaucoma Management**

*L. Rossetti (Germany)*

13:12 **Who Needs an Optimal Glaucoma Management? Patient Cases – Panel Discussion**

*G. Megavand, and Panel*

**Morning Sessions - Hall C**

---

**08:00 - 09:00 Challenging Case Session**

Hall C

Chairpersons: **Q. Nguyen, USA**  
**S. Lightman, UK**

---

**The Management of CNV in Uveitis**

*S. Taylor (UK)*

**Tapering Infliximab Therapy In a Quiescent VKH Case**

*R. Neumann (Israel)*

**Scleritis and PUK Intractable to Conventional IMT**

*W. Ayliffe (UK)*

---

**09:00 - 10:30 Biomarkers for Ocular Surface Disease & Free Papers**

Hall C

Chairperson: **P.A. Asbell, USA**

---

09:00 **Can Biomarkers Overcome the Limitations of Traditional Dry Eye Endpoints?**

*R.K. Brazzell (USA)*

09:10 **Biomarkers of Ocular Surface Inflammation**

*R. Beuerman, Z. Lei (Singapore)*

09:20 **Tear Hyper-osmolarity as a Biomarker for Dry Eye: Comparison of Osmolarity Measures by Electrical Impedance and Freezing Point Depression Techniques**

*A. Tomlinson, L. McCann, E. Pearce (UK)*

09:30 **Protein Biomarkers and Tear Film and Dry Eye Disease**

*F. Grus (Germany)*

09:40 **Lymphocytes Detection on the Ocular Surface of Dry Eye Patients**

*S. Barabino (Italy)*

09:50 **Dry Eye Disease: Correlating HLA-DR Expression with Clinical Severity**

*P. Asbell, E. Rosenberg, M. Massingale, S. Epstein, M. Vallabhajosyula, Y. Wei, M. Suzuki, C. Ghobrial, D. Brocks, G. Raynor, P. Dentone, S. Fukuoka, T. Petratos*  
USA

10:00 **Discussion Q&A**

10:20 **SIDE: The Surgically Induced Dry Eye**

*C. Feinbaum<sup>1</sup>, S. Patel<sup>2</sup>*

<sup>1</sup>Sweden, <sup>2</sup>Spain

10:30 - 11:00 **Coffee Break**

---

**Introduction and Welcome**

**11:00 Luveniq for Sight-Threatening Non-Infectious Uveitis: Results of the LUMINATE Trials, Lux Biosciences Presentation**

*J. Rosenbaum*<sup>1</sup>, *V. Gupta*<sup>2</sup>, *D. Scales*<sup>1</sup>, *T. Barisani-Asenbauer*<sup>3</sup>, *B. Bodaghi*<sup>4</sup>,  
*Q.D. Nguyen*<sup>1</sup>, *M. Zierhut*<sup>5</sup>, *C.S. Foster*<sup>1</sup>, *C. Pavesio*<sup>6</sup>, *G. Jaffe*<sup>1</sup>, *V. Sangwan*<sup>2</sup>  
<sup>1</sup> USA, <sup>2</sup> India, <sup>3</sup> Austria, <sup>4</sup> France, <sup>5</sup> Germany, <sup>6</sup> England

**Free Papers**

**11:20 Endophthalmitis: Operation Procedures and Different Antibiotic Therapies - The Mannheim Experience**

*F. Rensch*, *J. Jonas*, *F. Schlichtenbrede* (Germany)

**11:28 Effect of High Versus Low Oral Doses of Valacyclovir (VCV) on HSV-1 DNA Shedding into Tears of Latently Infected Rabbits**

*J. Hill*, *M. Kumar*, *C. Clement*, *D. Neumann*, *E. Varnell*, *H. Thompson*, *H. Kaufman*  
USA

**11:36 The Effect of Intracameral Injection of Vancomycin vs. Cefuroxime on Corneal Endothelium**

*S. Levartovsky*, *M. Vershinin*, *I. Kaiserman*, *G. Kleimann*, *O. Mahler*, *A. Polack*,  
*A. Marcovich*  
Israel

**11:45 - 12:30 Inspire & Infection Free Papers**

Hall C

Chairpersons: **M. Belkin**, Israel  
**K. Brazzell**, USA

---

**Inspire Presentation**

11:45 **Suitability of Topical Azithromycin for the Treatment of Blepharitis**  
*K. Brazzell (USA)*

**Free Papers**

12:05 **Electrical Sterilization of Eye Drops**  
*A. Golberg, M. Belkin, B. Rubinsky (Israel)*

12:13 **Topical Povidone-Iodine/Dexamethasone Reduced the Clinical Signs and Viral Titers in a Rabbit Model of Adenoviral Conjunctivitis**  
*J. Hill, C. Clement, M. Kumar, J. Palem, B. Liang, J. Capriotti, H. Thompson (USA)*

12:21 **Improper Storage Temperature, Defective Plastic Bottles, and the Worldwide Fusarium Keratitis Epidemic of 2004-2006**  
*J.D. Bullock (USA)*

Panel Members: R. Vogel, USA, B. Katz, USA, R. Neumann, Israel, P. Asbell, USA, K. Brazzell, USA, S. Lightman, UK, A. Okada, Japan

---

**Optimal Glaucoma Management Lunch Session, Sponsored by Allergan**

---

Main Presentations: Hall B

Overflow Screen: Hall C

**Afternoon Sessions - Hall A**

---

**14:00 - 15:45 Macular Edema** Hall A  
Chairpersons: **A. Pearson, USA**  
**D. Do, USA**

---

- 14:00 **Subtenon's Triamcinolone for the Treatment of Diabetic Macular Edema**  
*T.J. Wolfensberger (Switzerland)*
- 14:08 **Intravitreal Bioerudivel Sustained-Release Triamcinolone Microspheres System (RETAAC) for the Treatment of Diabetic Macular Edema**  
*J. Cardillo (Brazil)*
- 14:16 **Cortiject Dexamethasone Lipid Emulsion for the Treatment of Diabetic Macular Edema: A Pilot Study**  
*B. Kuppermann MD, PhD (USA)*
- 14:24 **Retisert Implant for the Treatment of Posterior Uveitis and Diabetic Macular Edema**  
*A. Pearson (USA)*
- 14:32 **Ozurdex for Uveitic Macular Edema**  
*M. deSmet<sup>1</sup>, R. Belfort, Jr<sup>2</sup>, C. Lowder<sup>3</sup>, C.S. Foster<sup>3</sup>, M. Robinson<sup>3</sup>, R.M. Schiffman<sup>3</sup>, X.Y. Li<sup>3</sup>, H. Cui<sup>3</sup>, S. Lightman<sup>4</sup>, S.M. Whitcup<sup>3</sup>*  
*<sup>1</sup>Switzerland, <sup>2</sup>Brazil, <sup>3</sup>USA, <sup>4</sup>UK*
- 14:40 **Ozurdex for DME: Results of a Randomized Controlled Trial of an Intravitreal Dexamthasone Drug Delivery System in Diabetic Macular Edema**  
*J.A. Haller (USA)*
- 14:48 **Illuvien Implant - Technology and Status of Current Clinical Trials**  
*A. Pearson (USA)*
- 14:56 **A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti-Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema**  
*V. Gonzalez (USA)*
- 15:04 **Update on the READ 2 Study: Ranibizumab for Diabetic Macular Edema**  
*D. Do, READ 2 Study Group (USA)*
- 15:12 **The RIDE and RISE Studies of the Efficacy and Safety of Intravitreal Ranibizumab (LUCENTIS®) in Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus**  
*Q.D. Nguyen, The RISE and RIDE Investigators (USA)*
- 15:20 **The DA VINCI Study: A Phase 2 Trial of VEGF Trap-Eye for Diabetic Macular Edema**  
*D. Do (USA)*

**14:00 - 15:45 Macular Edema (Cont.)**

Hall A

15:28 **ICo-007, a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy**

*V. Gonzalez*<sup>1</sup>, *P. Hnik*<sup>2</sup>

<sup>1</sup> USA, <sup>2</sup> Canada

15:45 - 16:15 **Coffee Break**

---

**16:15 - 17:00 Diabetic Retinopathy/PDR Treatment/Inhibition of DR Progression**

Hall A

Chairpersons: *A. Sjolie*, Denmark

*V. Gonzalez*, USA

---

16:15 **TA/Steroids for Inhibition of Progression of DR**

*M. Ip* (USA)

16:24 **Role of the Vitreous in Diabetic Retinopathy Progression**

*A. Gandorfer* (Germany)

16:33 **Intravitreal Injection of Pegaptanib Sodium for Proliferative Diabetic Retinopathy**

*V. Gonzalez* (USA)

16:42 **The Effect of the Angiotensin Receptor Blocker Candesartan on Progression and Regression of Diabetic Retinopathy**

*A.K. Sjolie* (Denmark)

16:51 **Vascular Toxicity of Steroids**

*F. Behar-Cohen* (France)

---

**17:00 - 17:45 Devices for Retinal Diseases**

Hall A

17:00 **Oily-Based Carriers for Intravitreal Sustained Drug Delivery**

*J. Garrigue*, *B. Philips*, *P. Daull*, *F. Lallemand* (France)

17:11 **Nanoparticles**

*F. Behar-Cohen* (France)

17:22 **Microspheres for Retinal Diseases**

*R. Herrero-Vanrell*, *I. Bravo-Osuna*, *D. Barbosa*, *P. Checa-Casalengua*,

*I.T. Molina-Martinez*

Spain

17:33 **The Role of Ischemia in AMD Progression as Manifested by the Retinal Function Imager (RFI)**

*Z. Burgansky-Eliash*, *A. Barak*, *A. Grinval*, *A. Loewenstein* (Israel)

**Afternoon Sessions - Hall B**

---

**14:00 - 15:45 Drug Delivery**

Hall B

Chairpersons: **D. Tang Liu**, USA  
**R. Gurny**, Switzerland

---

- 14:00 **Protein Delivery on the Posterior Segment of the Eye**  
*F. Behar-Cohen* (France)
- 14:11 **The Association of Avastin (Bevacizumab) with Dexamethasone: An In-Vitro Stability Study**  
*M. Veurink, C. Stella, C. Tabatabay, C. Pournaras, R. Gurny* (Switzerland)
- 14:22 **A Novel Drug Carrier System for the Delivery of Cyclosporine A to the Eye**  
*C. Di Tommaso*<sup>1</sup>, *K. Mondon*<sup>1</sup>, *J. Bourges*<sup>2</sup>, *F. Behar-Cohen*<sup>2</sup>, *R. Gurny*<sup>1</sup>,  
*M. Moller*<sup>1</sup>  
<sup>1</sup>Switzerland, <sup>2</sup>France
- 14:33 **Novel Water-Soluble Prodrug of Cyclosporine A for Ophthalmic Application**  
*M. Rodriguez-Aller, B. Kaufmann, C. Stella, D. Guillarme, R. Gatz, M. Geron, J. L. Veuthey, R. Gurny*  
Switzerland
- 14:44 **Advantages of Medicated Intraocular Lenses**  
*Y. Guex-Crosier, S. Eperon, M. Rodriguez-Aller, L. Bossy-Nobs, R. Gurny* (Switzerland)
- 14:55 **Accelerating scFv Antibody Fragments for Local Applications into the Clinic**  
*L. Borrás, T. Gunde, D. Urech* (Switzerland)
- 15:06 **Innovative Delivery Route for Antibodies in Ophthalmology**  
*M. Berdugo*<sup>1</sup>, *L. Feraille*<sup>1</sup>, *I.V. Larsen*<sup>3</sup>, *C. Abadie*<sup>2</sup>, *C. Deloche*<sup>2</sup>, *L. Kowalczyk*<sup>1</sup>,  
*E. Touchard*<sup>1</sup>, *Z. Chen*<sup>4</sup>, *P.P. Elena*<sup>1</sup>, *C.R. Brandt*<sup>3</sup>, *F. Behar-Cohen*<sup>1</sup>,  
*J.M. Combette*<sup>2</sup>  
<sup>1</sup>France, <sup>2</sup>Switzerland, <sup>3</sup>USA, <sup>4</sup>CA, USA
- 15:17 **Application of Encapsulated Cell Technology for Retinal Degenerative Diseases**  
*W. Tao* (USA)
- 15:28 **Effective Sustained Delivery of Dexamethasone to the Macula of Monkeys from a Solid Polymer Intravitreal Implant**  
*J. Burke, T. Lin, K. Zhang, W. Orilla, M. Escobar, A. Ghosn, J. Chang-Lin, L. Wheeler*  
USA
- 15:45 - 16:15 **Coffee Break**

**16:15 - 17:45 Ocular Infection**

Hall B

Chairperson: **I. Barequet**, Israel

---

- 16:15 **Novel Cell-Targeted Approaches to Adenovirus Keratoconjunctivitis**  
*J. Chodosh, J. Rajaiya, A. Chintakuntlawar (USA)*
- 16:25 **Ocular Antibacterial and Antiviral Testing in Animal Models: Limitations and Data Interpretation**  
*E. Romanowski (USA)*
- 16:35 **Discussion**
- 16:40 **The Ups and Downs of Fluoroquinolones for the Treatment of Ocular Bacterial Infections**  
*R. Kowalski (USA)*
- 16:50 **The Resistance Patterns of Normal Ocular Bacterial Flora to 4 Fluoroquinolone Antibiotics**  
*C.K. Joo (South Korea)*
- 17:00 **Discussion**
- 17:05 **Ocular Pharmacokinetics of Topical Azithromycin**  
*K. Tabbara (Saudi Arabia)*
- 17:17 **Discussion**
- 17:20 **Antibacterial Prophylaxis for Ophthalmic Surgery: The Present and The Future**  
*I. Barequet, Z. Habot-Wilner, J. Moisseiev, N. Keller (Israel)*
- 17:30 **Update on Improvements for Therapy of Severe Bacterial Endophthalmitis**  
*M.C. Callegan, D. Woods, S. Guess, N. Wheatley, B. Wiskur, R. Leonard (USA)*
- 17:40 **Discussion**

**Afternoon Sessions - Hall C**

---

**14:00 - 14:45 Devices of the Anterior Segment** Hall C  
Chairperson: **P.A. Asbell, USA**

---

- 14:00 **Evolving Indications for the Boston Keratoprosthesis**  
*J. Chodosh, J. Ciolino, C. Dohlman (MA, USA)*
- 14:09 **The surgical Treatment of the End Stage of Dry Eye Disease, with Falcinelli's**  
*G. Falcinelli (Italy)*
- 14:18 **Determination of Treatment Strategies for Granular Corneal Dystrophy Type 2 Using Fourier-Domain Optical Coherence Tomography**  
*T. Kim<sup>1</sup>, J.P. Hong<sup>1</sup>, B.J. Ha<sup>1</sup>, R.D. Stulting<sup>2</sup>, E.K. Kim<sup>1</sup>*  
*<sup>1</sup> Korea, <sup>2</sup> USA*
- 14:27 **Excimer Laser in Penetrating Keratoplasty**  
*B. Seitz, A. Langenbacher, G.O.H. Naumann (Homburg/Saar)*
- 14:36 **Corneal Collagen Crosslinking for Keratoconus: What Really Does Happen?**  
*R. Mencucci (Italy)*
- 

**14:45 - 15:45 Ocular Devices - Regulation** Hall C  
Chairpersons: **J. Alio, Spain**  
**M. Eydelman, USA**

---

- 14:45 **How to Get a Medical Device to Market in U.S.**  
*M. Eydelman (USA)*
- 14:54 **Update on EU regulations for medical devices**  
*K. Wickstrom (Sweden)*
- 15:03 **European Regulations for Medical Devices and Comparison with FDA Requirements**  
*B. Fant (USA)*
- 15:10 **Regulatory System of Medical Devices in Japan - From the Standpoint of a Physician**  
*M. Sawa (Japan)*
- 15:19 **EVI.CT.SE: Capabilities and Structure for the Investigation of Medical Devices in Cataract, Cornea and Refractive Surgery**  
*J. Alio<sup>1,2</sup>, J. Cunha Vaz<sup>3</sup>*  
*<sup>2</sup> Spain, <sup>3</sup> Portugal*
- 

15:45 - 16:15 **Coffee Break**

---

**16:15 - 17:45 Ethics: Relationship of Clinicians with the Industry**

Hall C

Chairpersons: **R. Vogel, USA**  
**R. Neumann, Israel**

---

**The Fate of Promising Ventures Facing Declining Economy: the Losers and the Winners and Are There Any?**

*B. Katz (USA)*

**The Characteristics and Regulation of the Physician/Industry Relationship**

*R. Vogel (USA)*

**Medical Affair – Bridging Medical/Ethical and Commercial Considerations Within the Industry**

*R. Neumann (Israel)*

**Panel Discussion: Moderator R. Vogel, USA**

**Panel Members:**

R. Vogel, USA, B. Katz, USA, R. Neumann, Israel, P. Asbell, USA, K. Brazzell, USA, S. Lightman, UK , A. Okada, Japan

**Morning Sessions - Hall A**

---

**08:00 - 09:45 S48 - Retina - Free Papers** Hall A  
Chairpersons: **F. Bandello**, Italy  
**E. Zrenner**, Germany

---

- 08:00 **Role of Arginase Activity in Acute Retinal Inflammation**  
*R. Caldwell, W. Zhang, B. Baban, M. Rojas, M. Romero, W. Caldwell (USA)*
- 08:10 **Improvement of Rods and Cones Function After Intravitreal Bevacizumab (Represented by Increase a-wave Electroretinogram Response) in Neovascular AMD Patients**  
*A. Skaat, I. Moroz, A. Solomon, Y. Rotenstreich (Israel)*
- 08:20 **TNFalpha is Required for Late BRB Breakdown in Diabetic Retinopathy and it Promotes Hyperoxia-Induced Apoptosis in Retinal Vessels and Neurons**  
*S.A. Vinores, H. Huang, J.K. Gandhi, X. Zhong (USA)*
- 08:30 **And Then There Were Three**  
*M. Zurria (Italy)*
- 08:40 **Role of Diuretics as a Risk Factor for Posterior Vitreous Detachment**  
*F. De Gregorio, G. Stecchi, S. Manganiello (Italy)*
- 08:50 **PKC-beta/HuR/VEGF Pathway in Diabetic Retinopathy**  
*C. Bucolo, A. Pascale, M.L. Amadio, S. Govoni, F. Drago (Italy)*
- 09:00 **18-Month Data from Patients Entering Wet AMD Extension Study Following CLEAR-IT 2 Randomized, Dose- and Interval-Ranging Phase 2 Study**  
*J.F. Korobelnik (France)*
- 09:10 **Optimizing Strategies for Bevacizumab Injections in ARMD: a Randomized Controlled Trial**  
*T. Lushchik, G. Baarsma, J. Martinez-Ciriano, L. Van den Born, T. Missotten  
The Netherlands*
- 09:20 **6-month Evaluation of an Intravitreal Dexamethasone Implant in Patients with Macular Edema Associated with Branch or Central Retinal Vein Occlusion**  
*F. Bandello<sup>1</sup>, J.A. Haller<sup>2</sup>, R. Belfort<sup>3</sup>, M. Gillies<sup>4</sup>, J.S. Heier<sup>2</sup>, A. Lowenstein<sup>5</sup>,  
Y. Yoon<sup>6</sup>, X. Li<sup>2</sup>, S.M. Whitcup<sup>2</sup>  
<sup>1</sup> Italy, <sup>2</sup> USA, <sup>3</sup> Brazil, <sup>4</sup> Australia, <sup>5</sup> Israel, <sup>6</sup> Korea*
- 09:30 **Blind Retinitis Pigmentosa Patients Can Read Letters and Combine them to Words with Subretinal Electronic Implants**  
*E. Zrenner, R. Wilke, K. Bartz-Schmidt, H. Benav, D. Besch, F. Gekeler, J. Koch,  
K. Porubska, H. Sachs, B. Wilhelm  
Germany*

**09:45 - 10:30 Vitreous**

Hall A

Chairpersons: **A. Gandorfer**, Germany  
**B. Kuppermann**, USA

---

09:45 **Transthyretin Levels in the Vitreous Correlate with Change in Visual Acuity after Vitrectomy**

*E. Van Aken*<sup>1</sup>, *E. De Letter*<sup>1</sup>, *M. Veckeneer*<sup>2</sup>, *L. Derycke*<sup>1</sup>, *T. Van Enschot*<sup>1</sup>,  
*I. Geers*<sup>1</sup>, *S. Delanghe*<sup>1</sup>, *J. Delanghe*<sup>1</sup>  
<sup>1</sup> Belgium, <sup>2</sup> the Netherlands

09:56 **Phase 2/3 Clinical Trials of Vitreosolve, A Urea Derived Molecule, For the Induction of Posterior Vitreous Detachment**

*B. Kuppermann*, *N. Mandava* (USA)

10:07 **Hyaluronidase (Vitrace®) for Enzymatic Vitreolysis**

*B. Kuppermann*, *E.L. Thomas* (USA)

10:18 **Microplasmin Treatment of Vitreoretinal Disease: Update on the Phase III MIVI-TRUST Program**

*A. Gandorfer* (Germany)

10:30 - 11:00 **Coffee Break**

**11:00 - 11:45 Retina - Free Papers**

Hall A

Chairpersons: **R. Lezzi, USA**  
**B. Kuppermann, USA**

---

- 11:00 **Haemorrhage in the Treatment of Age-Related Macular Degeneration**  
*H. Langrova, E. Rencova, M. Blaha, J. Studnicka, V. Blaha, G. Kyprianou, M. Lanska, P. Rozsival*  
*Czech Republic*
- 11:09 **Nanotechnology-Based Drug Delivery for Neuroprotection in Retinitis Pigmentosa and Age-Related Macular Degeneration**  
*R. Iezzi, R. Kannan, I. Glybina (USA)*
- 11:18 **Comparison of Two Doses of Intravitreal Bevacizumab as Primary Treatment for Macular Edema Secondary to Central Retinal Vein Occlusions at 24 Months**  
*L. Wu<sup>8</sup>, J.F. Arevalo<sup>1</sup>, M.H. Berrocal<sup>2</sup>, M. Maia<sup>3</sup>, J. Roca<sup>4</sup>, V. Morales-Canton<sup>5</sup>, A. Alezzandrini<sup>6</sup>, M. Diaz-Llopis<sup>7</sup>*  
*<sup>1</sup> Venezuela, <sup>2</sup> Puerto Rico, <sup>3</sup> Brazil, <sup>4</sup> Peru, <sup>5</sup> Mexico, <sup>6</sup> Argentina, <sup>7</sup> Spain, <sup>8</sup> Costa Rica*
- 11:27 **Bilateral Simultaneous Intravitreal Injections in the Office Setting**  
*S. Bakri, M. Risco, A. Edwards, J. Pulido (USA)*
- 11:36 **Intraoperative Complications of 1000 Consecutive Intravitreal Lucentis Injections**  
*P.K. Valavil (United Kingdom)*

**Morning Sessions - Hall B**

---

**08:00 - 09:00 Anterior Segment - Free Papers** Hall B  
Chairpersons: **H. Kaufman**, USA  
**Z. Habot-Wilner**, Israel

---

- 08:00 **Cacicol20, a New Matrix Therapy Device Improves Resistant Corneal Ulcers and Keratitis**  
*D. Barritault, C. Kamary, K. Kichenin, F. Brignole-Baudouin, H. Nourry, J.M. Warnet, C. Baudouin*  
*France*
- 08:08 **The Inhibitory Effect of Different Concentrations of Topical Bevacizumab on Corneal Neovascularization**  
*Z. Habot-Wilner, M. Rosner, Y. Ivanir, J. Moisseiev, I. Barequet (Israel)*
- 08:16 **A Combination Povidone-Iodine 0.4% Dexamethasone 0.1% Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis**  
*J. Pelletier<sup>1</sup>, K. Stewart<sup>1</sup>, W. Trattler<sup>1</sup>, D. Ritterband<sup>2</sup>, S. Braverman<sup>1</sup>, M. Samson<sup>2</sup>, B. Liang<sup>2</sup>, J. Capriotti<sup>1,2</sup>*  
*<sup>1</sup> USA, <sup>2</sup> NY*
- 08:24 **Randomised Controlled Trial Comparing Intracameral Cefuroxime and Moxifloxacin on Post-Phaco Endothelial Cell Count**  
*R. Mohd Saleh, A.R. Ropilah, K.Y. Then (Malaysia)*
- 08:32 **A Randomized, Comparative Study of Fluorometholone 0.1% and Loteprednol after Photorefractive Keratectomy**  
*I. Halkiadakis, S. Nikas, I. Metaxaki, N. Makris, S. Skouriotis, G. Amariotakis, A. Kandarakis, A. Amariotakis*  
*Greece*
- 08:40 **Assessing the Synergistic Potential of Antimicrobials for Bacterial Keratitis**  
*H. Sueke, C. Parry, S. Kaye, S. Tuft, Microbiology Ophthalmic Group (UK)*
- 08:48 **Herpes Simplex: Pathogenesis and Treatment of Ocular Disease**  
*H. Kaufman (USA)*

**09:00 - 10:30 Glaucoma - Free Papers**

Hall B

Chairperson: **P.K. Valavil**, UK

---

- 09:00 **Intravitreal Bevacizumab for Neovascular Glaucoma**  
*F. Rensch*<sup>1</sup>, *L. Golubkina*<sup>1</sup>, *T. Libondi*<sup>2</sup>, *J. Jonas*<sup>1</sup>  
<sup>1</sup>Germany, <sup>2</sup>Italy
- 09:10 **Safety and Efficacy of a New Fixed-Combination of Timolol-Brimonidine-Dorzolamide Versus Timolol and Dorzolamide Fixed Combination**  
*L. Baiza-Duran*, *J. Alvarez-Delgado*, *Y. Contreras-Rubio*, *J. Medrano-Palafox*,  
*H. Casab-Rueda*, *M. Cortes-Gastelum*, *J. Garciduenas-Mejia*, *F. Gil-Carrasco*,  
*C. Hartleben-Matkin*, *J. Jimenez-Roman*, *M. Moreno-Marin*, *A. Paczka-Zapata*,  
*G. Velasco-Gallegos*  
Mexico
- 09:20 **Surgical Efficacy of Seprafilm® on Trabeculectomy in Glaucoma Patients**  
*H. Ohguro*, *I. Ohguro*, *M. Tsuruta*, *S. Tanaka* (Japan)
- 09:30 **Antioxidant and Prooxidant Effects of Antiglaucoma Drugs**  
*A. Izzotti*, *S.C. Sacca'* (Italy)
- 09:40 **The Comparative Profile of 24-hour IOP Curves on Non-Glaucoma Patients Versus New Diagnosed, Untreated Glaucoma Patients**  
*A. Popa Cherecheanu*, *M. Ghita*, *R. Pascu* (Romania)
- 09:50 **Reduction of Bimatoprost-Induced Periocular Pigmentation with Topical Anti-Ultraviolet Cream**  
*C. Hartnett*, *M. Hickey-Dwyer* (Ireland)
- 10:00 **Effect of Dimethylenastron in Experimental Glaucoma Filtrating Surgery**  
*J. Lueke*, *K. Nassar*, *M. Lueke*, *A. Giannis*, *S. Grisanti* (Germany)
- 10:10 **Optic Disk Hemorrhage: a Clinical Model for Testing Neuroprotective Agents. Effects of Intramuscular Cytidine-5'diphosphocholine**  
*F. De Gregorio*, *G. Stecchi*, *C. Barozzi*, *R. Falchetti* (Italy)
- 10:20 **Latest NICE(National Institute of Clinical Excellence) Guidelines on Glaucoma in UK and Alterations in Service Provisions Needed to Comply with Guidelines**  
*P.K. Valavil* (UK)
- 10:30 - 11:00 **Coffee Break**

**11:00 - 11:45 Basic Science - Free Papers**  
Chairperson: **C. Paterson**, USA

---

Hall B

- 11:00 **Ocular and Optic Nerve Ischemia Treated with Prostaglandin E1**  
*R.D. Steigerwalt Jr, A. Pascarella, G. Belcaro, C. M Rosaria (Italy)*
- 11:11 **Effects of Cytochrome P450 2D6 (CYP2D6) Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryopreserved Hepatocytes**  
*M. Volotinen, T. Korjamo, A. Tolonen, M. Turpeinen, O. Pelkonen, J. Maenpaa, J. Hakkola*  
*Finland*
- 11:22 **Alkylphosphocholines as a Potential Treatment for Proliferative Ophthalmic Diseases**  
*K. Eibl-Lindner, R. Liegl, M. Kernt, A. Wolf, C. Haritoglou, A. Gandorfer, A. Kampik*  
*Germany*
- 11:33 **Effect of Vitamin Supplementation on Vascular Reactivity in Response to Hyperoxia in an Endotoxin Induced Model of Oxidative Stress**  
*G. Garhofer, B. Pemp, E. Polska, L. Schmetterer (Austria)*